This retrospective study was undertaken to evaluate cure rates, toxicity and late effects of early intensive therapy followed by autologous stem cell transplantation (ASCT) in patients with advanced Hodgkin's disease (HD). One hundred and fifty-eight cases of ASCT registered in the French database (SFGM) were retrospectively analyzed. Disease status at the time of ASCT was first partial response (PR) in 85, first complete remission (CR1) in 45 or primary refractory in 28 cases. The median time interval between diagnosis and ASCT was 7 months (range 4-13). At the time of analysis in December 1995, 121/158 patients (76.6%) were alive, including 111 (70.2%) in continuous CR with a median follow-up for surviving patients of 46 months (range 8-123). Peri-ASCT toxic death rate was 3%, and the actuarial risk of new malignancies was 4.9% at 5 years. The cumulative probability of 5-year overall survival (OS) was 75.2% for the entire group of patients, 80.6% for the chemosensitive ones, and 33.9% for the primary refractory (chemosensitive vs refractory, P Ͻ 0.0001). The cumulative probability of 5-year event-free survival (EFS) was 66.1% for the entire group of patients, 73.7% for the chemosensitive ones, and 26.1% for the primary refractory (chemosensitive vs refractory, P Ͻ 0.0001). The only significant prognostic factor for both OS and EFS was disease status at the time of ASCT. Early ASCT in advanced HD is feasible, with a low risk of toxicity and without a higher rate of late effects compared with conventional treatment. Results achieved in chemosensitive patients at the time of transplantation lay the basis of future prospective randomized trials comparing ACST as front-line treatment to conventional treatment in high-risk cases.
Most patients with advanced Hodgkin's disease (HD) may now be cured using combination chemotherapy or combined modality therapy (CMT). However, 20 to 40% of these patients relapse after completion of the primary treatment. 1 In this group of patients, autologous stem cell transplantation (ASCT) has been widely investigated and progression-free survival (PFS) rates of 25 to 60% have been reported. [2] [3] [4] [5] [6] [7] [8] In this setting, the British National Lymphoma Investigation group has demonstrated in a randomized trial that high-dose therapy followed by ASCT improved both event-free survival (EFS) and PFS as compared with conventional-dose treatment. 9 Thus, many authors recommend transplant to patients after relapse from any front-line chemotherapy regimen regardless of the duration of initial remission. 10 We and others have given intensive therapy followed by ASCT earlier in the course of the disease as part of frontline treatment in young patients at high risk of failure. These few pilot studies including small numbers of selected patients have described high response rates, [11] [12] [13] [14] but the clinical benefit of early ASCT is still controversial. Longterm follow-up in large series of patients is requisite to address the important issues of efficacy and toxicity, ie peri-ASCT toxic death rate and other potential late-occurring complications related to immunosuppression and treatment-induced oncogenesis, of such a procedure.
The current study was undertaken to evaluate cure rates, toxicity and late effects of early intensive therapy followed by ASCT in a group of 158 patients with advanced HD registered in the French data base.
Patients and methods

Patients
Between January 1986 and December 1995, a total of 158 adult patients with HD who received early ASCT being either in first partial reponse (PR1), first complete response (CR1) or primary refractory (Ref) after initial conventional chemotherapy have been reported to the registry of the French Society of Bone Marrow Transplantation (SFGM) from 18 centers. All patients who received ASCT after a first relapse were excluded from this analysis. Registration details on all these patients were reviewed. All reporting physicians were contacted to provide additional information on patients' characteristics at presentation and follow-up. No central pathology review was undertaken. Patients were staged according to the Ann Arbor system. 15 Patients' characteristics are listed in Table 1 . Selection criteria for induction chemotherapy, ie MOPP, ABVD or a combination of the two protocols were not specified. Selection criteria for early ASCT varied from one center to another but in all cases ASCT was planned at diagnosis either as consolidation therapy after achieving a good response to initial treatment in patients with high-risk disease, 13 or as an intensification therapy in case of high-risk disease with slow or no response to initial chemotherapy. 12 Disease status at the time of ASCT for all patients was evaluated according to the classification described by Philip et al. 16 CR1 was defined as the resolution of all diseaserelated symptoms and normalization of all initial physical examination and imaging abnormalities, PR1 as a reduction of more than 50% in all measurable lesions, and any response less than 50% was considered refractory. One hundred and thirty patients were treated with high-dose therapy in first response, either CR1 in 45 or PR1 in 85 cases, while 28 patients were primary refractory to initial chemotherapy. Most of the patients with chemosensitive disease (95/130, 73%) received only one chemotherapy regimen before ASCT, while patients with primary refractory disease never experienced response despite two or three chemotherapy regimens before ASCT ( Table 1) .
The median time interval from diagnosis to ASCT was short: 7 months (range, 4-13 months) ( Table 2 ). 
Source of autologous stem cells
Fifty-one percent of patients received autologous bone marrow (BM) as the sole source of stem cell rescue. Peripheral blood stem cells (PBSC) were used in 49%, mainly in those registered during the last 4 years of the study period (Table 2) .
High-dose regimens
The high-dose regimens are listed in Table 2 . Regimens that included fractionated 12 Gy total body irradiation (TBI) were used in only 6% of patients. The remaining 94% received chemotherapy-only high-dose regimens, with carmustine, etoposide, cytarabine, and melphalan (BEAM) or cyclophosphamide, carmustine, and etoposide (CBV). Sixty-nine percent of patients received adjuvant radiotherapy on residual masses, either immediately before the conditioning regimen (24%) with a median dose of 26 Gy (24 to 54 Gy) or immediately after hematological recovery (45%) with a median dose of 35 Gy (20 to 40 Gy) ( Table 2) .
Supportive care
Supportive care was given according to standard procedures and active protocols in each participating institution. The use of hematopoietic growth factors also varied between institutions, the most commonly used being granulocyte colony-stimulating factor (G-CSF) ( Table 2) .
Statistical analyses
Actuarial survival curves were constructed according to the method of Kaplan and Meier. 17 Overall survival (OS) was calculated from the day of stem cell reinfusion to the date of death from any cause. Event-free survival was calculated from the day of stem-cell reinfusion to the date of documented relapse or progression, the date of death from any cause, or the date of documented myelodysplasia or second cancer. Univariate analysis was performed using the logrank test to identify factors that predicted for OS and EFS. Multivariate analysis was performed using the Cox proportional hazards regression method. The prognostic factors included in these analyses were as follows: status at ASCT (CR1 vs PR1 vs Ref, chemosensitive vs chemoresistant disease), source of stem cells (BM vs PBSC), type of highdose therapy (CBV vs BEAM vs TBI-containing regimen), sex, age (18 to 28, ie median age in this series vs Ͼ28 years and 18 to 45 vs Ͼ45 years), and when these data were available: bone marrow involvement at diagnosis, inguinal involvement at diagnosis, large mediastinal mass (tumor/thorax Ͻ0.45 vs Ͼ0.45), serum LDH level at diagnosis (normal vs Ͼ normal value), hematocrit level at diagnosis (normal vs Ͻ normal value), extra-nodal localizations at diagnosis (Ͻ2 vs у2), lymphocyte count at diagnosis (normal vs Ͻ normal value), albumin level at diagnosis (normal vs Ͻ normal value).
Results
Response and survival
Currently 121/158 patients (76.6%) are alive, including 111 (70.2%) in continuous CR with a median follow-up of 46 months for surviving patients (range 8-123 months). Nine patients are alive in relapse, and one is alive with a myelodysplastic syndrome (MDS) diagnosed 24 months after ASCT. Thirty-seven (23.4%) have died, 27 (17.1%) due to relapse or progressive HD, and 10 (6.3%) due to transplantrelated complications. The cumulative probability of 5-year OS is 75.2% for the entire group of patients, 80.6% for the chemosensitive ones (82.8% in PR1 vs 76.3% in CR1, P = 0.49), and 33.9% for the primary refractory, (chemosensitive vs refractory P Ͻ 0.0001, Figure 1 ). The cumulative probability of 5-year EFS is 66.1% for the entire group of patients, 73.7% for the chemosensitive (75.5% in PR1 vs 69.9% in CR1, P = 0.41), and 26.1% for the primary refractory, (chemosensitive vs refractory P Ͻ 0.0001, Figure 2 ).
Prognostic factors for OS and EFS
For the entire group, only two factors both in univariate and multivariate analysis were predictive for OS: mediastinal mass Ͼ0.45 (P = 0.0357 in multivariate analysis) and disease status at the time of ASCT (sensitive vs refractory, P = 0.0003 in multivariate analysis). The latter parameter was the only one to predict for EFS (P = 0.001).
Toxicity
Engraftment: Five patients who died before day +30 were not evaluable for hematologic recovery ( Table 2 ). All 153 evaluable patients engrafted. The median time to achieve a platelet count Ͼ20 × 10 9 /l without platelet transfusion was 16 days (range 4-120). The median time to reach an absolute neutrophil count (ANC) Ͼ0.5 × 10 9 /l was 14 days (range 6-40), and was significantly reduced for patients who received hematopoietic growth factors (G-or GM-CSF) compared with those who did not (median 11 days, range 6 to 14 vs median 17 days, range 10-40, P = 0.007 Wilcoxon's rank sum test). There was no significant difference in the rate of granulocyte (P = 0.87) and platelet recovery (P = 0.76) among patients receiving autologous BM or PBSC.
Nonrelapse mortality: Ten patients (6.3%) died of nonrelapse causes. Five toxic deaths (3%) due to infectious complications were observed within the first month after transplantation, two of them in patients receiving hematopoietic Second malignancies: For the whole group of patients, the actuarial risk of new malignancies was 4.9% at 5 years. Three patients (crude incidence 2%) developed therapyinduced MDS 21, 24 and 35 months, respectively, after ASCT. Two of them were refractory at the time of ASCT and had received three different chemotherapy regimens before transplantation. One additional patient developed lung cancer 38 months after transplantation, leading to death.
Discussion
Despite few pilot studies including small numbers of patients, 11-14 early intensive therapy followed by ASCT in advanced HD remains to be evaluated. This series of 158 patients shows the feasibility of such a strategy. The procedure-related mortality in the first 90 days post-ASCT was 3%, due to infectious complications. No veno-occlusive disease or interstitial pneumonitis were observed. This low toxic death rate is similar to that reported with ASCT performed as part of first-line treatment for multiple myeloma 18 or non-Hodgkin's lymphoma (NHL). 19 The crude 2% incidence of MDS and the 4.9% actuarial incidence of second malignancies at 5 years in this large cohort of patients does not appear to be higher than that described after conventional therapy in stage IIIB/IV HD. Although the follow-up was longer in the study from Stanford University (Stanford, CA, USA), the mean 15-year actuarial risk of all second cancers including MDS, leukemia or solid tumor (ST) after various conventional therapies was 17.6%. 20 More recently, Viviani et al 21 reported a 4% crude incidence of second malignancies in the 10-year results of a MOPP/ABVD combination chemotherapy trial in 427 cases of advanced HD. Salloum et al 22 also described, after a prolonged follow-up of 13.5 years, a 13.8% crude incidence of second malignancies after CMT in 116 patients, including eight cases of MDS or leukemia, and five cases of ST. In transplanted patients, Miller et al 23 reported a cumulative incidence of MDS of 14.5% at 5 years. In their study of 206 patients treated for HD or NHL, patients received a median of 14 cycles of chemotherapy before ASCT, emphasizing the cumulative leukemogenic potential of standard and salvage radiation and chemotherapy regimens including high-dose therapy. Traweek et al 24 reported after ASCT for HD or NHL a cumulative probability of developing clonal cytogenetic changes, and thus subsequent MDS or acute leukemia, of 9% at 8 years. In this series, the mean time interval from diagnosis to ASCT was 2.7 years, and the majority of patients received ASCT after a relapse. With the same median time interval from diagnosis to ASCT of 28 months, the risk appears to be lower in Chopra's series, who reported only two cases of MDS out of 155 transplantations after the BEAM conditioning regimen in a single center 8-year study. 4 Darrington et al 25 reported an estimated cumulative incidence of MDS and secondary leukemia of 4% at 5 years in a one-center study of 511 ASCT for lymphoid malignancies, and they estimated that the probability of MDS or leukemia among patients with HD alive at 5 years was 11%. Post-autologous 791 Table 3 Results of prospective and randomized trials testing chemotherapy or CMT in advanced HD transplant-associated MDS is undoubtedly a risk of such a therapy, but the pretransplant chemotherapy itself may possibly play a role in causing this complication. Some authors even recommend transplanting patients earlier in the course of their disease to lower the rate of this complication.
26
In our series, disease status at the time of transplantation is of major importance. Even if the number of cases with refractory disease is relatively small, our data (5-year EFS, 26.1 Ϯ 9.26%) confirm the poor prognosis of this subset of patients. Similar results have been reported by the London group, 4 with a 33% PFS rate at 6 years (95%, confidence interval 21-50%) in a population of 46 patients with primary refractory HD treated with the BEAM regimen. The team from Stanford University recently reported results with high-dose therapy and autografting that appeared to be better than ours in patients with refractory HD, with 5-year EFS rate from 48 to 53%. 7, 8 These results were achieved in patients who were not truly refractory, but in patients with induction failure who subsequently responded to salvage therapy and who presented, in most cases, with minimal disease at the time of transplantation. In our series, refractory cases were patients with either progressive disease or no response at the time of ASCT. Such refractory patients have a very poor prognosis with conventional-dose salvage therapy with reported long-term survival less than 15%. 27 In the small population of primary refractory cases, the PFS rate of 20-40% achieved by ASCT suggests that dose escalation may rescue some of these patients. Nonetheless, new therapeutic approaches, such as two-staged ASCT for example, 28 are warranted. On the other hand, results of early ASCT in responding patients are encouraging. The 5-year 73.7% EFS in chemosensitive cases at the time of ASCT compares favorably with results of conventional treatments in advanced cases. Analysis of the results of eight prospective trials testing chemotherapy alone or CMT in newly diagnosed advanced HD published after 1990 shows that the EFS rate ranges from 45 to 75% at 5 years in such patients (Table 3) . 21, [29] [30] [31] [32] [33] [34] [35] However, we cannot conclude that the results of early ASCT are identical to those of conventional therapy for at least two reasons. First, in this retrospective study taken from a registry analysis, patients who had undergone highdose therapy and autografting may have been selected with predictably better outcomes. Secondly, the prognosis of patients treated for advanced HD is highly influenced by a number of unfavorable characteristics at presentation (age Ͼ45 years, mediastinal mass Ͼ0.45 the thoracic diameter, elevated serum lactic acid dehydrogenase, hematocrit below normal, marrow involvement, albumin level below normal [36] [37] [38] [39] [40] ) that have to be comparable in series of patients treated with transplantation or with conventional therapy. Thus, the comparison between high-dose and conventional therapy requires a randomized study with an intent-to-treat analysis from diagnosis to avoid the bias mentioned above. Such a trial should take into account the difficulty in classifying patients as responders, either partial or complete, or refractory after initial treatment and especially at the time of transplantation. Assessment of responses should be evaluated according to accurate definitions, as recently defined by Connors et al, 34 for example. In conclusion, the use of early intensive therapy followed by ASCT in advanced HD is feasible, with a low risk of early toxicity and without a higher rate of late effects compared with conventional treatment. The encouraging results achieved in chemosensitive patients at the time of transplantation lay down the basis of future prospective randomized trials comparing ASCT as front-line treatment to conventional treatment in high-risk cases.
